Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 9/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6854212 | 0.99 | SMPD1 (0.44) | SMPD1GGPS1LPAR3LPAR1LPAR2 | |
| SCHEMBL11024893 | 0.88 | SMPD1 (0.56) | SMPD1GGPS1LPAR3LPAR1LPAR2 | |
| SCHEMBL11021842 | 0.88 | SMPD1 (0.56) | SMPD1GGPS1LPAR3LPAR1LPAR2 | |
| Monoethanolamine SCHEMBL27656170 | 0.82 | SMPD1 (0.51) | SMPD1GGPS1LPAR3LPAR1LPAR2 | |
| Monoethanolamine SCHEMBL27867926 | 0.82 | SMPD1 (0.51) | SMPD1GGPS1LPAR3LPAR1LPAR2 | |
| SCHEMBL9115436 | 0.81 | PLA2G2C (0.43) | SMPD1GGPS1LPAR3LPAR1LPAR2 | |
| SCHEMBL8472151 | 0.80 | PLA2G2C (0.41) | SMPD1GGPS1LPAR3LPAR1LPAR2 | |
| SCHEMBL19471840 | 0.79 | GPR55 (0.45) | SMPD1GGPS1 | |
| SCHEMBL10596171 | 0.79 | GPR55 (0.45) | SMPD1GGPS1 | |
| SCHEMBL5962134 | 0.77 | LPAR1 (0.43) | LPAR3LPAR1LPAR2LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011091167-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR TARGETING FOR SCLERODERMA AND OTHER FIBROTIC DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100239501-A1 | GENE SENSITIVE TO BONE/JOINT DISEASE AND USE THEREOF | RIKEN (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20100143381-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR TARGETING FOR LUNG DISEASE | THE GENERAL HOSPITAL CORPORATION | 2010-06-10 | — | — | US | disclosed |
| EP-2153847-A1 | GENE SENSITIVE TO BONE/JOINT DISEASE AND USE THEREOF | Riken (JP) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008112201-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR TARGETING FOR LUNG DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| EP-1918287-A2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1263752-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1613298-A4 | LYSOPHOSPHATIDIC ACID ANALOGS AND INHIBITION OF NEOINTIMA FORMATION | UNIV TENNESSEE RES FOUNDATION (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1427424-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1613298-A2 | LYSOPHOSPHATIDIC ACID ANALOGS AND INHIBITION OF NEOINTIMA FORMATION | The University of Tennessee Research Foundation (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6875757-B2 | For therapy of cancer, enhancing cell proliferation, and wound | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-05 | — | — | US | disclosed |
| WO-2004091496-A2 | LYSOPHOSPHATIDIC ACID ANALOGS AND INHIBITION OF NEOINTIMA FORMATION | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040204383-A1 | Lysophosphatidic acid analogs and inhibition of neointima formation | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE | 2004-10-14 | — | — | US | disclosed |
| EP-1427424-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1263752-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2003024402-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-06 | — | — | US | disclosed |
| EP-1263752-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001071022-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | SMPD1 145/4885GGPS1 778/4885LPAR3 3/4885 |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR5 | SMPD1 112/4885GGPS1 1147/4885LPAR3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.